Tissue Repair Ltd · ASX:TRP
Tissue Repair — Shareholder Meeting (November 2022)
15 slides from Tissue Repair's shareholder meeting presentation, Nov 23, 2022
Slide 1: Glucoprime hydrogel
For personal use only Glucoprime® hydrogel (TR987® for chronic wounds; TR P r o + TM f o r d a m a g e d o r w o u n d e d s k i n ) This announcement has been approved for release by TRP’s board. tissuerepair.com.au | trproplus.com
Slide 2: Important notice and disclaimer
Important notice and disclaimer This presentation (Presentation) is dated 7 November 2022 and has been prepared by Tissue Repair recommendation to acquire any securities in the Company and does not take into consideration the Ltd (ACN 158 411 566) (Tissue Repair or the Company). investment objective
Slide 3: Executive Summary
Executive Summary Unique platform Differentiated drug label Phase 3 clinical Commercialisation of aftercare For personal use only technology strategy provides trials commencing in product for medical and valuable opportunity 2023 cosmetic treatments • Technology platform is a • Core focus is on real
Slide 4: Unique technology
Unique technology • The immunomodulatory mechanism of action seeks to offer significant clinical For personal use only benefits to patients undergoing treatment for acute or chronic wounds including: o closure for wounds which have stalled and become chronic; The Benefits o lower cost of hospitalisa
Slide 5: Glucoprime – Mechanism of action
Glucoprime® – Mechanism of action • There is recognition of the Glucoprime®- containing hydrogel by receptors on macrophages For personal use only within the tissue. Macrophages are the ‘guard’ cells that protect against invaders. • Two receptors, dectin-1 and TLR2, are engaged and trick the body in
Slide 6: Two indications targeting different conditions
Two indications targeting different conditions For personal use only Stage of clinical development Commercial Market Product Strategy Preclinical Ph 1 Ph 2A Ph 2B Ph 3 launch • Achieve FDA and TGA approval as a topical drug Clinical trial 2025 Primary (following #1 Chronic for use in venous leg ulce
Slide 7: Clinical Study – chronic wounds (2020)
Clinical Study – chronic wounds (2020) For personal use only Phase 2B: Study of the Efficacy of TR 987, beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers (BG001, Australia/USA, 2020). To assess the time to heal within 12 weeks between chronic VLUs treated with TR987® gel
Slide 8: Key product advantages – TR987 for chronic wounds
Key product advantages – TR987® for chronic wounds For personal use only • No drug or biologic appears to have been approved in chronic wounds since REGRANEX gel in 1997, and as such a drug Strong efficacy signal indication for chronic wounds supported by high quality clinical data drives reimbursem
Slide 9: Milestones and initiatives – TR987 for chronic wounds
Milestones and initiatives over the short-to-medium term – TR987® for chronic wounds Completed Planned For personal use only • Completion of FDA Type C meeting with positive outcomes • Initiation of a 28-day minipig study as part of for raw material, CMC and abridged toxicology program the toxicolog
Slide 10: Clinical Study – laser skin resurfacing (2020)
Clinical Study – laser skin resurfacing (2020) For personal use only Phase 2B: Study to Evaluate a Novel Macrophage Activating Gel for Optimization of Healing and Skin Quality After CO2 Laser Resurfacing of the Chest (TR987-2016-FullChest, USA, 2020). To evaluate the efficacy of TR Pro+ TM active ge
Slide 11: Real-world evidence study (2022)
Real-world evidence study (2022) A real-world evidence study(1) was done with 12 dermatology clinics in Australia in patients (n=48) who had For personal use only undergone a range of cosmetic and medical procedures. The program was run independently and patients provided anonymous feedback at day 6
Slide 12: Milestones and initiatives – TR Pro+
Milestone and initiatives over the short-to-medium term – TR Pro+TM for the aftercare of cosmetic and medical procedures Completed Planned For personal use only • Comprehensive market research program • Commercial launch of TR Pro+TM to undertaken with various healthcare professional dermatology and
Slide 13: Milestones and initiatives – additional developments
Milestone and initiatives over the short-to-medium term – additional developments Completed Planned For personal use only • Two patents accepted which each afford 21 years • A third patent application is being prepared to of protection: cover the structure of the beta glucan • claims to the method o
Slide 14: Corporate overview
Corporate overview For personal use only Key financial details (8 November 2022) Major Shareholders # of shares % Cash at bank 30 September 2022 $24.385million SELENE HOLDINGS LTD 5,955,980 9.85% Market capitalisation $17.5million SPARK CAPITAL PTY LIMITED AND TONY CHARARA 4,895,336 7.98% Share pric
Slide 15: For personal use only
For personal use only